Trial Profile
Phase I Study of T Cells Expressing an Anti-CD19 Chimeric Receptor in Children and Young Adults With B Cell Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 Sep 2022
Price :
$35
*
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 01 Sep 2022 Results analyzing neurotoxicity of CD19/CD28zeta CAR T-cells in CAYA treated on NCT01593696, published in the Neuro-Oncology
- 25 Mar 2021 Results published in the Journal of Clinical Oncology
- 03 Oct 2017 Status changed from active, no longer recruiting to completed.